Physicians may earn 10.0 AMA PRA Category 1 Credits™.

Nurses may accrue up to 10 continuing education contact hours.

Course Description:

The annual Frontiers in Pediatric Genomic Medicine Conference brings leaders in research, industry and healthcare together to explore advances in translating genomic diagnostics into targeted treatment for patients in neonatal and pediatric intensive care. This year's program will focus on the topics of Rapid Whole Genome Sequencing in Behavioral Health & Neuro-Oncology and Newborn Genomic Sequencing

Learning Objectives:

At the conclusion of this conference, the participants should be able to:

• Describe the principles of genomic medicine and whole genome sequencing. Discuss the uses, benefits, and limitations of genomic testing technologies. Recognize the implications of implementing genomic medicine in NICUs and PICUs.
• Recognize when and how to refer patients for whole genome sequencing.
• Identify tools and other practical resources for implementation of whole genome sequencing.
• Determine early ascertainment for patients who may benefit from whole genome sequencing.
• Recognize how to collaborate with an interdisciplinary team of health professionals.

Target Audience:

This activity is intended for the Genomic Community.

Needs Assessment:

Genomic medicine is a new healthcare approach that utilizes various technologies to accurately identify patients with specific variations in human genes that result in disease and mortality. It is a large, somewhat diffuse field of study that encompasses diverse disciplines. While the practice of whole genomic sequencing could be a key technology leveraged by NICUs and PICUs to assist in making treatment decisions of acutely-ill babies, a pediatric genomic medicine knowledge gap currently exists between many healthcare providers in the United States. Genomic medicine is a relatively recent development in the healthcare sphere introduced only 15 years ago with the completion of the first human genome. Incorporating genomics into clinical decision making has only been feasible with the advent of improved technologies allowing cost-effective genomic analysis. Genomic diagnostic and decision-making tools are being developed at a higher rate now than ever before. Unfortunately, didactic coursework in healthcare curricula that prepares healthcare professionals to utilize genomic medicine has been slow to catch up. This has left many practicing healthcare professionals in the workforce without formal training in pediatric genomic medicine, which is hampering the adoption of genomics in the care of acutely-ill children.

Disclosures:

It is the policy of University of California San Diego School of Medicine Continuing Professional Development to ensure that the content of accredited continuing education and related materials is accurate, balanced, objective, and scientifically justified. Education must be free of the influence or control of ineligible companies, and protect learners from promotion, marketing, and commercial bias.  All persons in a position to control the content of accredited continuing education must disclose all financial relationships held with ineligible companies, prior to assuming a role in the activity. Those relationships deemed relevant to the education are mitigated prior to the activity through one of the following strategies, depending on the nature of relationship and the role of the person: 1) divesting the financial relationship, 2) altering the individual’s control over content, and/or 3) validating the planning decisions and/or content through independent peer review. All relevant financial relationships are mitigated prior to the activity and mitigation strategies and necessary steps for implementation are communicated to individuals prior to them assuming their role in the activity. Persons who refuse or fail to disclose are disqualified from participating in the activity.  Activities are evaluated by participants and peer reviewers to determine if the content was free of bias and met acceptable scientific standards. This information is considered in future activity planning.  All relevant financial relationships and the nature of those relationships are noted below.  All relevant financial relationships have been mitigated.

Faculty Member Name	Role in Activity	Name of Ineligible Company(ies)/Nature of Relationship(s)
Stephen F Kingsmore, MBBS, FRCPath	Course Director	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Springer-Nature|Membership on Advisory Committees or Review Panels, Board Membership, etc.-|Grant or research support-Alexion Pharmaceuticals|Grant or research support-Amgen, Inc.|Grant or research support-Chiesi Farmaceutici|Grant or research support-Fabric Genomics|Grant or research support-Genomenon Inc.|Grant or research support-Helix Inc.|Grant or research support-Horizon Therapeutics|Grant or research support-Illumina Inc.|Grant or research support-Ionis Pharmaceuticals|Grant or research support-Inozyme Pharma|Grant or research support-Mahzi Therapeutics|Grant or research support-Nest Genomics|Grant or research support-Orchard Therapeutics|Grant or research support-Rocket Pharma|Grant or research support-Sanofi S.A.|Grant or research support-Sarepta Therapeutics|Grant or research support-Sentinyl Therapeutics|Grant or research support-TileDB Inc.|Grant or research support-Travere Therapeutics Inc.|Grant or research support-Ultragenyx
Jonathan Douglas Santoro, MD	Faculty	Consulting Fee-UCB|Consulting Fee-Cycle Pharmaceuticals|Consulting Fee-TG Therapeutics
Diana Azzam, PhD	Faculty	Scientific Advisor - First Ascent Biomedical
Robin Knight, PhD	Faculty	Advisor-Biota tehnology|Advisor-GenCirq, Inc. |Advisor-DayTwo, Ltd.|Consulting Fee-Cybele Microbiome, Inc. |Consulting Fee-BiomeSense,Inc. |Advisor-Micronoma, Inc.
Jennifer H Yang, MD	Faculty	Grant or research support-Astellas (Any division)|Grant or research support-Stealth

• The University of California, San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
• The University of California, San Diego School of Medicine designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• Continuing medical education (CME) providers are required by state Assembly Bills 1195 and 241, and the standards created by the California Medical Association (CMA), to include components that address cultural and linguistic competency and implicit bias in CME activities. The planners and presenters of this activity has been asked to provide meaningful consideration of these standards in the selection and presentation of content. Additional information and resources are available on the UC San Diego CME website.